Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial)
American Journal of Cardiology, Volume 124, No. 12, Year 2019
Notification
URL copied to clipboard!
Description
Q-wave myocardial infarction (QWMI) comprises 2 entities. First, a clinically evident MI, which can occur spontaneously or be related to a coronary procedure. Second, silent MI which is incidentally detected on serial electrocardiographic (ECG) assessment. The prevalence of silent MI after percutaneous coronary intervention (PCI) in the drug-eluting stent era has not been fully investigated. The GLOBAL LEADERS is an all-comers multicenter trial which randomized 15,991 patients who underwent PCI to 2 antiplatelet treatment strategies. The primary end point was a composite of all-cause death or nonfatal new QWMI at 2-years follow-up. ECGs were collected at discharge, 3-month and 2-year visits, and analyzed by an independent ECG core laboratory following the Minnesota code. All new QWMI were further reviewed by a blinded independent cardiologist to identify a potential clinical correlate by reviewing clinical information. Of 15,968 participants, ECG information was complete in 14,829 (92.9%) at 2 years. A new QWMI was confirmed in 186 (1.16%) patients. Transient new Q-waves were observed in 28.5% (53 of 186) of them during the follow-up. The majority of new QWMI (78%, 146 of 186) were classified as silent MI due to the absence of a clinical correlate. Silent MI accounted for 22.1% (146 of 660) of all MI events. The prevalence of silent MI did not differ significantly between treatment strategies (experimental vs reference: 0.88% vs 0.98%, p = 0.5027). In conclusion, we document the prevalence of silent MI in an all-comers population undergoing PCI in this large-scale randomized trial. © 2019 Elsevier Inc.
Authors & Co-Authors
Modolo, Rodrigo G.P.
Netherlands, Amsterdam
Amsterdam Umc - University of Amsterdam
Tomaniak, Mariusz
Netherlands, Rotterdam
Erasmus Mc
Poland, Warsaw
Medical University of Warsaw
Hoole, Stephen Paul
United Kingdom, Cambridge
Royal Papworth Hospital Nhs Foundation Trust
Gori, Tommaso
Germany, Mainz
Universitätsmedizin Mainz
Zaman, Azfar G.
United Kingdom, Newcastle
University of Newcastle Upon Tyne, Faculty of Medical Sciences
Bertrand, Olivier François
Canada, Quebec
Université Laval
Sousa, Amanda Guerra De Moraes Rego
Brazil, Sao Paulo
Instituto Dante Pazzanese de Cardiologia
van Geuns, Robert Jan M.
Netherlands, Rotterdam
Erasmus Mc
Netherlands, Nijmegen
Radboud University Medical Center
Steg, Philippe Gabriel
France, Paris
Ap-hp Assistance Publique - Hopitaux de Paris
Hamm, Chrisitian Wilhelm
Germany, Bad Nauheim
Kerckhoff-klinik Gmbh
Germany, Berlin
Deutsches Zentrum Für Herz-kreislauf-forschung E. V.
Jüni, Peter
Canada, Toronto
Li ka Shing Knowledge Institute
Canada, Toronto
University of Toronto
Vranckx, Pascal
Belgium, Hasselt
Universiteit Hasselt
Valgimigli, Marco
Switzerland, Bern
University Hospital Bern
Windecker, Stephan W.
Switzerland, Bern
University Hospital Bern
Serruys, Patrick W.
United Kingdom, London
Imperial College London
Soliman, O. I.I.
Netherlands, Rotterdam
Erasmus Mc
Netherlands, Rotterdam
Cardialysis bv
Onuma, Yosinobu
Netherlands, Rotterdam
Erasmus Mc
Netherlands, Rotterdam
Cardialysis bv
Statistics
Citations: 6
Authors: 17
Affiliations: 22
Identifiers
Doi:
10.1016/j.amjcard.2019.08.049
ISSN:
00029149
Study Design
Randomised Control Trial
Cross Sectional Study
Cohort Study